
OPCH Stock Forecast & Price Target
OPCH Analyst Ratings
Bulls say
Option Care Health demonstrated a robust financial performance, with gross profit reaching $269.0 million, reflecting an 8% year-over-year increase that exceeded expectations. The company’s chronic therapy business recorded growth exceeding 10%, contributing to a positive trend in revenue generation. Furthermore, Option Care Health raised its 2025 revenue estimate to $5.61 billion, anticipating a 12% year-over-year growth, alongside an upward adjustment in its overall financial guidance.
Bears say
Option Care Health Inc. faces challenges with its general and administrative (G&A) expenses, which are expected to decline slowly relative to revenue, potentially impacting profitability. The company encounters significant revenue dependency, as its largest customer accounted for 14% of its 2023 revenue, making it vulnerable to substantial financial repercussions should it lose this client. Additionally, the anticipated gross profit headwind related to Stelara, estimated at over $20 million for the quarter, poses further risks to EBITDA margin expansion amid a shift toward lower-margin chronic therapies.
This aggregate rating is based on analysts' research of Option Care Health and is not a guaranteed prediction by Public.com or investment advice.
OPCH Analyst Forecast & Price Prediction
Start investing in OPCH
Order type
Buy in
Order amount
Est. shares
0 shares